The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma

Basit Öğe Kaydı
dc.authoridBİÇİM, SOYKAN/0000-0001-7498-344X
dc.authoridSARICI, Ahmet/0000-0002-5916-0119
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridUYSAL, AYŞE/0000-0002-5581-8104
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authorwosidBİÇİM, SOYKAN/ACZ-6163-2022
dc.authorwosidSARICI, Ahmet/ABI-7512-2020
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidUYSAL, AYŞE/HJB-3073-2022
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.contributor.authorUysal, Ayse
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKuru, Irfan
dc.contributor.authorKaya, Emin
dc.contributor.authorBerber, Ilhami
dc.contributor.authorSarici, Ahmet
dc.contributor.authorBicim, Soykan
dc.date.accessioned2024-08-04T20:54:29Z
dc.date.available2024-08-04T20:54:29Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ mu L in the peripheral blood (PB) on the 4th day of mobilization.Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined.Results: The median CD34+ cell count in PB on the 4th day was 5.2/mu L (0.1-13.4), which was determined to increase 206.6-fold (31.5749347) to 924.80 /mu L (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= - 872.2; p<0.0001). The number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106).Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.en_US
dc.identifier.doi10.5472/marumj.1244684
dc.identifier.endpage71en_US
dc.identifier.issn1309-9469
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85164248915en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage65en_US
dc.identifier.urihttps://doi.org/10.5472/marumj.1244684
dc.identifier.urihttps://hdl.handle.net/11616/101454
dc.identifier.volume36en_US
dc.identifier.wosWOS:000926968200011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMarmara Univ, Fac Medicineen_US
dc.relation.ispartofMarmara Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectApheresisen_US
dc.subjectStem cellen_US
dc.subjectMobilizationen_US
dc.subjectPlerixaforen_US
dc.subjectPreemptiveen_US
dc.titleThe effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu